Xando Díaz-Villamarín

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent

Jesús Sánchez-Ramos, Cristina Lucía Dávila-Fajardo, Pablo Toledo Frías et al. · International Journal of Cardiology · 2016 · 63 citations

Thrombosis, Percutaneous Coronary Intervention, Cardiovascular Disease +11

Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

Margarita-Ioanna Koufaki, Vasileios Fragoulakis, Xando Díaz-Villamarín et al. · Human Genomics · 2023 · 30 citations · Full text

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

Hoi Y. Tong, Cristina Lucía Dávila-Fajardo, Alberto M. Borobia et al. · PLoS ONE · 2016 · 22 citations · Full text

Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation

Xando Díaz-Villamarín, Emilio Fernández-Varón, Michelle Carolina Rojas Romero et al. · Biomedicine & Pharmacotherapy · 2023 · 17 citations · Full text